Artgen Biotech PJSC (MOEX:ISKJ)

Russia · Delayed Price · Currency is RUB

59.54

+0.84 (1.43%)

At close: Jul 8, 2022

55.78% (1Y)

Market Cap	4.29B
Revenue (ttm)	1.72B +12.8%
Net Income	96.95M -54.9%
EPS	1.29 -55.4%
Shares Out	71.99M
PE Ratio	46.16
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	261,910
Open	59.30
Previous Close	58.70
Day's Range	59.12 - 61.82
52-Week Range	36.83 - 177.00
Beta	0.03
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Artgen Biotech PJSC

Artgen Biotech PJSC, a biotech company, engages in the development of healthcare products in Russia. It develops Betuvax-CoV-2, a vaccine for SARS-COV-2; Tetraflubet, a Flu vaccination; Combi 5V, a Flu + COVID-19 booster vaccine; Betusphere for Immunomodulator; RBT-402, a HPV vaccine; and RBT-501, a vaccine for natural allergy. The company also offers Histograft, a Gene-activated material used as an osteoplastic material, as well as biobanking, genetic research, and regenerative medicine services. In addition, it develops various medical produc... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2003

Country Russia

Stock Exchange Moscow Stock Exchange

Ticker Symbol ISKJ

Full Company Profile

Financial Performance

In 2025, Artgen Biotech PJSC's revenue was 1.72 billion, an increase of 12.80% compared to the previous year's 1.52 billion. Earnings were 96.95 million, a decrease of -54.89%.

Financial Statements